Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 27  |  Issue : 4  |  Page : 636-642

Intravitreal versus subtenon injection of triamcinolone acetonide for diabetic macular edema

1 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Ophthalmology, Shibin El-Kom Ophthalmology Hospital, Menoufia, Egypt

Correspondence Address:
Aml Mohamed Hamdy Abd El-Razik
Shibin El-Kom Ophthalmology Hospital, Menoufia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-2098.149629

Rights and Permissions

Objective The aim of this study was to compare the results of intravitreal injection with subtenon injection of triamcinolone in diabetic macular edema (DME). Background Triamcinolone injection for DME. Patents and methods The study is a prospective randomized clinical trial including 80 eyes of patients with DME. Patients were divided into two groups: group I and group II. Group I (73.1% men and 26.9% women; mean age 55.7 ± 7.2 years) included 40 eyes that received 4 mg of intravitreal triamcinolone acetonide injection. Group II (65.5% men and 34.5% women; mean age 55.8 ± 7.9 years) comprised 40 eyes that received 40 mg of subtenon triamcinolone acetonide injection. The patients were followed up after 1 week and 1, 3, and 6 months later to assess best-corrected visual acuity, intraocular pressure, and macular thickness. Fluorescein angiography and optical coherence tomography were used to evaluate the improvement. Results There was a statistically significant difference between the studied groups at 1 week and 1 month (P < 0.05) and no significant difference at 3 and 6 months (P > 0.05) as regards their post-treatment outcome for visual acuity, and there was no statistically significant difference between the studied groups at 1 and 6 months (P > 0.05) as regards their post-treatment outcome for macular thickness. Conclusion Both intravitreal and subtenon triamcinolone injections cause a significant increase in visual acuity; the effect is early and more pronounced in the intravitreal group but subtenon injection is safer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded136    
    Comments [Add]    

Recommend this journal